10:39 AM EDT, 03/11/2025 (MT Newswires) -- Quanterix ( QTRX ) shareholder Kent Lake said Tuesday that it opposes the company's proposed deal with Akoya Biosciences ( AKYA ) .

Kent Lake, which owns 7.25% of Quanterix's ( QTRX ) stock, argued the deal is bad for Quanterix ( QTRX ) shareholders as it values Akoya almost five times higher than Quanterix ( QTRX ), despite Quanterix's ( QTRX ) "superior" growth and market opportunity.

Kent Lake said in its claims that Quanterix ( QTRX ) ended up bidding against itself for Akoya, as other potential buyers backed out. It also raised concerns about the Quanterix ( QTRX ) board, suggesting that some directors have conflicts of interest and have not acted in the best interests of shareholders.

Kent Lake urged Quanterix ( QTRX ) stockholders to vote against the proposed merger and also said it recently nominated three independent board candidates to represent shareholders' interests better.

Quanterix ( QTRX ) and Akoya Biosciences ( AKYA ) did not immediately reply to MT Newswires' request for comments.

QTRX shares were up 3.5% and AKYA shares were 5.2% higher in recent trading.

Price: 7.53, Change: +0.25, Percent Change: +3.43